Hiring?
Logo

Axis Spinal

Short Summary

World-leading implant technology. £3.25m Forecast 2021. 820 configurations. Backed by Mercia EIS fund. Team ex GSK, a 25 year veteran of spine implants, a PhD in spinal disc replacement and a highly experienced J&J spine design engineer.

Overview

Target
US$3,900,000
Minimum
US$33,000
Investment Raised
US$2,600,000
Previous Rounds US$1
Stage Achieving Sales
Investor Role

Highlights

  • Surgeons can achieve 840 different implant configurations
  • Forecasting £3.25m in sales in next 12 months
  • Considerable interest from strong network of US spinal surgeons
  • Backed by Mercia EIS fund who will reinvest in this round
  • Team ex GSK, a 25 year veteran of spine implants a a PhD in spinal discs
Please note: Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. This information has not been approved as a financial promotion, and you must carry out your own due diligence.

Ask a question

Got a question about this project?

Sign up to view the full pitch

It's free to discover the next big thing

Already have an account?

Similar Projects

0% raised

Botanica Pharmaceutics

location_on London, United Kingdom

Botanica specialises in medical cannabis cultivation and the extraction of active pharmaceutical ingredients from biomass material. Our work is aimed at producing quality API ingredients and delivering new products to market at scale.

US$ 6,600,000

Target

US$ 3,300,000

Min per Investor

Global Pro
24% raised

BreedCo-MEDICAL CANNABIS

location_on Colombia

BreedCo: Cultivating, processing & selling medical cannabis derivatives & genetics; 1 of 3 companies globally able to export regulated cannabis genetics; pristine land; 95+ yrs cross-team experience; $32m valuation; Previously raised £3mn+; 5k% ROI...

US$ 330,000

Target

US$ 6,600

Min per Investor

Global Pro
50% raised

End Lockdown-UK Gov funds

location_on South East, United Kingdom

Unlike existing Covid-19 tests ours identifies infectious people before symptoms occur, at home in seconds. Crucial to stop spread by unknowing carriers. Low cost, award-winning, peer-reviewed, patent-pending, smartphone-based. Gov funding allocated.

US$ 660,000

Target

US$ 13,000

Min per Investor

load one similar proposal